A

Adaptimmune Therapeutics plc
D

ADAP

0.32970
USD
0.02
(7.67%)
مغلق
حجم التداول
0
الربح لكل سهم
-0
العائد الربحي
-
P/E
-1
حجم السوق
84,809,371
أصول ذات صلة
L
LINK
0.08000
(1.23%)
6.60000 USD
S
SOL
-0.07500
(-4.59%)
1.56000 USD
V
VET
-0.89700
(-10.94%)
7.30000 USD
المزيد
الأخبار المقالات

العنوان: Adaptimmune Therapeutics plc

القطاع: Healthcare
الصناعة: Biotechnology
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.